Shanberge J N, Quattrociocchi-Longe T M, Martens M H
Thromb Res. 1987 Apr 1;46(1):89-100. doi: 10.1016/0049-3848(87)90209-x.
To determine the interaction of platelet factor 4 (PF4) and protamine sulfate in the neutralization of heparin in plasma in vitro studies were carried out using a tritium-labeled heparin and a PF4 tagged with 14C. Plasmas treated with various combinations of PF4, protamine and heparin were chromatographed on Sephadex G200 and the fractions were tested for both radioactivity and antithrombin activity. PF4 was comparable to protamine in its ability to neutralize heparin, but the complexes formed with heparin were different. In contrast to protamine, when heparinized plasma was treated with an excess of PF4, no large PF4-heparin complexes were formed and none of the PF4-heparin complexes which did form were able to activate antithrombin III (ATIII). Also, incubation of PF4-neutralized, heparinized plasma at 37 degrees C did not result in liberation of heparin and prolongation of the thrombin clotting time as was found with protamine-neutralized plasma. The action of protamine and PF4 is complimentary. When half the neutralizing dose of each was added together to heparinized plasma, no immediate antithrombin activity remained. When a neutralizing dose of protamine was added to PF4-neutralized, heparinized plasma, the protamine displaced the PF4 from its complexes with heparin. The large protamine-heparin complexes which formed also contained PF4 but could not activate fresh ATIII as has been demonstrated with protamine-heparin complexes without PF4. On incubation of the protamine-PF4-neutralized, heparinized plasmas for 5 hours at 37 degrees C, the large complexes were broken down but no active heparin appeared. The results of these experiments may have some bearing on the amount of protamine needed for the neutralization of heparin following extracorporeal bypass procedures, when large amounts of PF4 may have been released from activated or disrupted platelets.
为了确定血小板第4因子(PF4)与硫酸鱼精蛋白在体外血浆中中和肝素的相互作用,使用氚标记的肝素和用14C标记的PF4进行了研究。用PF4、鱼精蛋白和肝素的各种组合处理的血浆在葡聚糖凝胶G200上进行色谱分析,并对各组分进行放射性和抗凝血酶活性检测。PF4中和肝素的能力与鱼精蛋白相当,但与肝素形成的复合物不同。与鱼精蛋白相反,当用过量的PF4处理肝素化血浆时,不会形成大的PF4-肝素复合物,并且所形成的PF4-肝素复合物均不能激活抗凝血酶III(ATIII)。此外,在37℃孵育PF4中和的肝素化血浆不会导致肝素释放和凝血酶凝血时间延长,而鱼精蛋白中和的血浆则会出现这种情况。鱼精蛋白和PF4的作用是互补的。当将每种物质的一半中和剂量一起加入肝素化血浆中时,不再有即时的抗凝血酶活性。当将中和剂量的鱼精蛋白加入PF4中和的肝素化血浆中时,鱼精蛋白会将PF4从其与肝素的复合物中置换出来。形成的大鱼精蛋白-肝素复合物中也含有PF4,但不能像不含PF4的鱼精蛋白-肝素复合物那样激活新鲜的ATIII。在37℃将鱼精蛋白-PF4中和的肝素化血浆孵育5小时后,大复合物分解,但没有活性肝素出现。这些实验结果可能与体外循环手术后中和肝素所需的鱼精蛋白量有关,此时可能已从活化或破裂的血小板中释放出大量PF4。